Halozyme Therapeutics, Inc.
HALO
$49.22
-$1.02-2.02%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 25.65% | 22.44% | 21.35% | 12.88% | 22.41% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 25.65% | 22.44% | 21.35% | 12.88% | 22.41% |
| Cost of Revenue | -1.86% | -17.13% | -9.99% | -5.39% | 6.90% |
| Gross Profit | 36.69% | 41.41% | 36.97% | 21.69% | 29.99% |
| SG&A Expenses | 9.94% | 3.45% | 17.48% | 13.51% | 1.25% |
| Depreciation & Amortization | -0.21% | -0.31% | 22.37% | 5.51% | 16.76% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.18% | -5.18% | 5.63% | 5.17% | 10.00% |
| Operating Income | 56.48% | 62.16% | 42.20% | 23.37% | 42.70% |
| Income Before Tax | 54.27% | 59.94% | 51.00% | 43.75% | 72.93% |
| Income Tax Expenses | 63.08% | 69.39% | 36.84% | 41.34% | 62.53% |
| Earnings from Continuing Operations | 52.25% | 57.71% | 54.57% | 44.32% | 75.52% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 52.25% | 57.71% | 54.57% | 44.32% | 75.52% |
| EBIT | 56.48% | 62.16% | 42.20% | 23.37% | 42.70% |
| EBITDA | 46.86% | 50.41% | 38.69% | 20.03% | 37.71% |
| EPS Basic | 57.10% | 63.48% | 61.49% | 50.70% | 83.74% |
| Normalized Basic EPS | 64.59% | 71.40% | 52.23% | 34.42% | 57.81% |
| EPS Diluted | 55.18% | 62.32% | 60.60% | 50.85% | 84.62% |
| Normalized Diluted EPS | 63.33% | 70.67% | 52.12% | 34.94% | 59.13% |
| Average Basic Shares Outstanding | -3.10% | -3.88% | -4.50% | -4.36% | -4.60% |
| Average Diluted Shares Outstanding | -2.38% | -3.60% | -4.57% | -4.77% | -5.47% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |